Steve Martin
Board Member @Ensysce Biosciences
Signup · Get unlimited contacts
WORK HISTORY
Board Member @Ensysce Biosciences
San Diego, CA, US
Ensysce Biosciences Inc, is a privately-held, clinical stage biotech company developing a new class of prescription drugs, Trypsin Activated Abuse Protection (TAAP) with overdose protection (MPAR) that will provide patients and prescribers safer options for use of potent opioid analgesia, reducing misuse and deaths from overdose. In addition, Ensysce is exploring the use of an ingredient from its overdose protection technology, nafamostat, for the treatment of COVID-19.
EDUCATION
San Diego State University
Bachelor of Science (B.S.), Accounting
SKILLS
ABOUT STEVE MARTIN
Experienced Senior Executive and Chief Financial Officer with overall management and operational experience that has driven organizations to achieve their mission and goals. Have successfully served the dual role of Interim CEO and CFO for two publicly-traded operating companies. Hands-on experience balancing opportunity and risk to develop highly effective finance organizations for new and growing public companies. Began my career for 10 years as a CPA at Deloitte and Touche before transitioning into Controller, VP Finance and CFO roles. As a strategic leader and Chief Financial Officer at Stratagene (2007) and BakBone Software (2011), I lead both through successful public company exit transactions. In addition to extensive SEC, M&A and IPO experience, I have broad involvement in fund-raising, shareholder relations, legal, insurance, contracts, human resources, banking relations, internal controls, and other corporate administrative and governance matters for both small and medium sized private and public companies. Having worked closely with Boards of Directors, Venture Capital investors and other stakeholders, I have the ability to gain consensus, driving and building shareholder value. Public or private company Board positions are an area of interest – with an ability to serve as “Financial Expert” and Audit Committee Chairman.Specialties: Public companies, Technology, Life Sciences, Software, Manufacturing, SEC matters, IPO\'s, Mergers and Acquisitions
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.